Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Highlevel overall survival OS results from the TROPIONLung01 Phase III trial which previously met the dual primary endpoint of progressionfree survival PFS numerically favoured datopotamab deruxtecan DatoDXd compared to docetaxel in the overall trial population of patients with locally advanced or metastatic nonsmall cell lung cancer NSCLC treated with at least one prior line of therapy.
Launch of 20 new medicines expected by 2030
Significant growth from existing oncology, biopharmaceuticals and rare disease portfolios
Investing in disruptive innovation that will shape the future.